NIH consensus development statement on hydroxyurea treatment for sickle cell disease.
National Institutes of Health consensus and state-of-the-science statements are prepared by independent panels of health professionals and public representatives on the basis of (1) the results of a systematic literature review prepared under contract with the Agency for Healthcare Research and Quality (AHRQ), (2) presentations by investigators working in areas relevant to the conference questions during a 2-day public session, (3) questions and statements from conference attendees during open discussion periods that are part of the public session, and (4) closed deliberations by the panel during the remainder of the second day and morning of the third. This statement is an independent report of the panel and is not a policy statement of the NIH or the U.S. Government.The statement reflects the panel's assessment of medical knowledge available at the time the statement was written. Thus, it provides a "snapshot in time" of the state of knowledge on the conference topic. When reading the statement, keep in mind that new knowledge is inevitably accumulating through medical research.
Brawley
Otis W
OW
Cornelius
Llewellyn J
LJ
Edwards
Linda R
LR
Gamble
Vanessa Northington
VN
Green
Bettye L
BL
Inturrisi
Charles E
CE
James
Andra H
AH
Laraque
Danielle
D
Mendez
Magda H
MH
Montoya
Carolyn J
CJ
Pollock
Brad H
BH
Robinson
Lawrence
L
Scholnik
Aaron P
AP
Schori
Melissa
M
D000293:Adolescent; D000328:Adult; D000755:Anemia, Sickle Cell / Q000188:drug therapy*; D000986:Antisickling Agents / Q000009:adverse effects / Q000627:therapeutic use*; D035843:Biomedical Research; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000009:adverse effects / Q000627:therapeutic use*; D007223:Infant; D008297:Male
D000986:Antisickling Agents; D006918:Hydroxyurea